Project Grant P01HL173579
Award Date
5/15/25
Completion Date
4/30/30
Dollars Obligated
$2.4M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This Project Grant award of $603,504 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to comprehensively characterize genetic variants related to von Willebrand Factor (VWF) secretion. The objectives are to: 1) use high-throughput techniques to map the effects of VWF gene variants on secretion, and 2) identify other genes critical for VWF secretion through CRISPR/Cas9 screens in cell lines. This work...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,276,908 to Bloodworks (formerly Puget Sound Blood Center and Program) to conduct molecular and translational research on the mechanisms of disease in von Willebrand disease and sickle cell disease. The research aims to increase understanding of these blood disorders, identify new biomarkers, and explore potential new...
This $1,779,777 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to elucidate the role of the GAB2-MALT1 signaling pathway in endothelial cells and its contribution to venous thrombosis. The research aims to: 1) Determine the molecular mechanisms by which GAB2 mediates thromboinflammatory signaling in endothelial cells, 2) Investigate the role of endothelial GAB2-MALT1 signaling in...
This $827,665 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837) supports research to develop scalable methods for identifying causal genetic variants, relevant cell types, and target genes that influence cardiovascular disease (CVD) risk. The key products and services to be delivered include: Performing colocalization of CVD and blood cell trait genome-wide association studies (GWAS) to...
This Project Grant award, with an ID of R01HL173322, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The total funding amount is $1,449,454.00 and the award date is July 15, 2024, with an ultimate completion date of June 30, 2028. The overall goal of this grant is to characterize the role of Factor XII (FXII) in the thrombo-inflammatory complications of sickle cell disease (SCD), including...
This $608,874 federal Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to decipher the links between leukocyte (white blood cell) activation and infections in patients with ventricular assist devices (VADs), devices implanted to help failing hearts. The key objectives are to: (1) identify pre-implant biomarkers that predict post-implant infection risk, (2) determine if high infection rates in...
This $601,677 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to characterize the molecular mechanisms underlying vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but dangerous side effect of adenoviral-vectored vaccines. The University of Massachusetts, Amherst will serve as the prime grantee, collaborating with researchers at McMaster University School of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $5,154,906.00 in funding to Versiti Wisconsin, Inc. to conduct a multi-disciplinary investigation of the molecular mechanisms underlying clinically important immune-mediated thrombocytopenic and thrombotic disorders. The research program, which involves collaboration with the Children's Hospital of Philadelphia, focuses on examining the...
This Project Grant award of $2,814,824.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS), under the federal Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award supports a multi-year research initiative led by the Washington University to investigate the pathogenesis of cerebral small vessel disease (CSVD) and vascular contributions to dementia (VCID). The key objectives are to: 1) identify...
This $704,635 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, is funding research to develop optimized adeno-associated virus (AAV) vector constructs for gene therapy of hemophilia. The primary awardee, the University of Florida, is conducting research to combine capsid and genome modifications to AAV3 vectors to improve their transduction efficiency and therapeutic expression in human...